

8ª Giornata dello specializzando in Neurologia - Catania, 11 giugno 2019

ANTI-RI-ASSOCIATED PARANEOPLASTIC OPHTHALMOPLEGIA-ATAXIA SYNDROME IN A WOMAN WITH BREAST CANCER

Manuela Mancini,¹ Andrea Quattrone,¹ Marco Casaletto,² Angelo Pascarella,¹ Alessia Giugno,¹
Angelo Labate,^{1,2} Antonio Gambardella.^{1,2}

Sporadic ataxia with adult onset: classification and diagnostic criteria

Thomas Klockgether

	Associated cancer	Other paraneoplastic syndromes
Anti-Yo (PCA-1)	Gynaecological, breast	..
Anti-Hu (ANNA-1)	SCLC	PEM, PSN
Anti-Tr	Hodgkin's lymphoma	..
Anti-Ri (ANNA-2)	SCLC, gynaecological, breast	Opsoclonus myoclonus syndrome
Anti-mGluR1	Hodgkin's lymphoma	..
Anti-CV2 (CRMP5)	SCLC, thymoma	PEM
Anti-ZIC4	SCLC	..
Anti-VGCC	SCLC	LEMS


Adapted from Dalmau and Rosenfeld,³⁵ with permission from Elsevier. ANNA-1/2=anti-neuronal nuclear antibody type 1/2. CRMP5=collapsin response mediator protein 5. LEMS=Lambert-Eaton myasthenic syndrome. mGluR1=metabotropic glutamate receptor type 1. PCA1=Purkinje cell antibody type 1. PEM=paraneoplastic encephalomyelitis. PSN=paraneoplastic sensory neuropathy. SCLC=small-cell lung cancer. VGCC=voltage-gated calcium channel. ZIC4=zinc finger protein 4.

Table 1: Autoantibodies in paraneoplastic cerebellar degeneration

Neuronal autoantigens—pathogenesis, associated disorders and antibody testing

Eric Lancaster and Josep Dalmau

Antibodies to intracellular antigens



T-cell mediated mechanisms

Table 1 Neuronal nonsynaptic autoantibody targets and associated syndromes					
Antigen	Antigen function	Tumour association	Syndromes	Mechanisms	Prognosis
Hu proteins (primarily HuD, but also HuC, Hel-N1 and Hel-N2) ¹¹²	HuD is important for neuronal RNA handling, cell-cycle regulation and cell development ^{113,114}	Small-cell lung cancer ¹¹⁵	Neuropathy (often purely sensory), cerebellitis, limbic encephalitis, autonomic dysfunction and/or brainstem encephalitis	Antibodies are not directly pathogenic; possibly T-cell-mediated	20% survival at 3 years (encephalitis is slightly more likely to cause death than is cancer)
Collapsin response mediator protein 5	Regulation of neurite outgrowth, and neurogenesis ¹¹⁶	Small-cell lung cancer and thymoma ¹¹⁷	Neuropathy, uveoretinal symptoms, ataxia or limbic encephalitis ¹¹⁷	Possibly T-cell-mediated ²²	Longer survival than with anti-Hu syndromes (48 versus 11 months) ¹¹⁷
Ma1 ¹¹⁸	Promotion of apoptosis	Diverse (lung, skin, gastrointestinal and renal)	Limbic encephalitis, cerebellitis, brainstem encephalitis or polyneuropathy	Probably T-cell-mediated rather than antibody-mediated ²¹	In a series of 13 patients, nine deteriorated, three stabilized and one improved ¹¹⁹
Ma2 (also known as Ta) ¹¹⁸	Not known	Germ cell tumours (especially in young men)	Limbic encephalitis, brainstem encephalitis, polyneuropathy or cerebellitis ¹¹⁹	Not known	In a case series 33% improved, 21% stabilized and 46% deteriorated ¹¹⁹
Yo proteins (also known CDR1 and CDR2)	CDR1 is strongly expressed in Purkinje cells; function unknown ¹²⁰ CDR2 may be involved in cell cycle regulation, mitosis, and transcriptional regulation ¹²¹	Specific to women Almost all are eventually diagnosed with breast or gynaecological cancer ¹²²	Paraneoplastic cerebellar degeneration	Conflicting data in patients regarding a role for T cells ^{27,28} Antibodies trigger neuronal cell death in slice culture ²⁹	Tumours may respond, but neurological symptoms are often unresponsive ¹²²
Ri proteins (also known as Nova-1 and Nova-2)	Nova-1 is an RNA-binding protein expressed by subcortical neurons Function of Nova-2 is not known	Breast cancer	Nova-1: cerebellar degeneration, encephalitis, myelitis, opsoclonus myoclonus ^{123,124} Nova-2: paraneoplastic opsoclonus myoclonus ataxia, ¹²⁵ myoclonus, encephalitis, cerebellar degeneration and myelitis	Antibodies may prevent binding of Nova-1 to RNA ¹²⁶ Unclear whether antibodies are pathogenic; comorbid antibodies are common and can occur in asymptomatic cancer patients ¹²⁷	Three of six patients improved; median survival >69 months in one series ¹²³
Tr	Found in Purkinje neurons; ¹²⁸ function not known	Hodgkin lymphoma	Paraneoplastic cerebellar degeneration ¹²⁹	Not known	Relatively good; median survival >113 months ¹²³
Zinc finger protein ZIC 4	Important for brain development	Small-cell lung cancer	Paraneoplastic cerebellar degeneration ¹³⁰	Antibodies may not be pathogenic; 80% of patients have other antibodies as well	Not known
Gephyrin and GABARAP	Associated with GABAergic transmission	Gephyrin: mediastinal carcinoma GABARAP: not known	Stiff-person syndrome ^{131,132}	Not known	Not known

Abbreviations: GABA, γ-aminobutyric acid; GABARAP, GABA receptor-associated protein.

Case Report



- The patient is a 72-year-old right-handed woman with a three-month history of **blurred vision, diplopia and progressive gait disturbance.**
- Family history was negative for neurological disorder.
- She was also on therapy for arterial hypertension and type 2 (non-insulin-dependent) diabetes mellitus.


Neurological Examination

Severe gait and truncal ataxia

Pupillary responses were normal

Asymmetric bilateral horizontal gaze paresis, left worse than right

Horizontal nystagmus



Laboratory findings







- ✓ Normal routine hematological and biochemical investigations, as well as serum blood gases, ammonia, vitamin B12, folate.
- ✓ Normal urinalysis.
- ✓ Negative screen for anti-nuclear, anti-DNA, anti-mitochondrial, anti-microsomal, anti-endomysial, and anti-gliadin autoantibodies.

**Cerebrospinal fluid
examination**




- Mild lymphocytic pleocytosis (30 cells/mm³)
- Positive oligoclonal bands





Whole-Body CT scan

Left nipple nodule



Left axillary adenopathy



Echo-guided biopsy of the axillary node confirmed lymph node metastasis and she underwent a **breast-conserving surgery**, lumpectomy with left axillary node dissection.

Onconeural antibodies

INTENSITA' CLASSE RISULTATO

RISPOSTA: ANTI Amfifisina	0	0	NEGATIVO
ANTI CV2	0	0	NEGATIVO
ANTI PNMA2/Ta	0	0	NEGATIVO
ANTI Ri	107	+++	POSITIVO
ANTI Yo	1	0	NEGATIVO
ANTI Hu	0	0	NEGATIVO
ANTI Recoverina	4	0	NEGATIVO
ANTI SOX 1	1	0	NEGATIVO
ANTI Titina	3	0	NEGATIVO
ANTI ZIC 4	0	0	NEGATIVO
ANTI GAD 65	0	0	NEGATIVO
ANTI Tr (DNER)	3	0	NEGATIVO

INTENSITA'	CLASSE	RISULTATO
0-5	0	NEGATIVO
5-10	(+)	BORDERLINE
10-25	+	POSITIVO
25-50	++	POSITIVO
50-100	+++	POSITIVO

EUROLineScan - Protocollo

Protocollo: PARANEOPLASTICI 230519
Operato da: Marco Casaletto

Data: 23/05/2019
Stampati: 23/05/2019

N	Patient / Test	Lotto	Strip
1	636/100519 Neuro_PNS12	103-78	PNS12/ 103-78 

EUROLINE PNS - 12 Ag

Etichetta, Etichetta, Controllo, Controllo, GAD65, Tr (DNER), Zic4, GAD65, Titin, Zic4, SOX1, Titin, Recoverin, SOX1, Hu, Recoverin, Yo, Hu, Ri, Yo, PNMA2/Ta, Ri, CV2, PNMA2/Ta, Amphiphysin, CV2, Amphiphysin

Anti-Ri: An Antibody Associated with Paraneoplastic Opsoclonus and Breast Cancer

F. Antonio Luque, MD, PhD,*† Henry M. Furneaux, PhD,*‡ Reuven Ferziger, AB,*‡ Marc K. Rosenblum, MD,†
Shirley H. Wray, MD, PhD,§ S. Clifford Schold, Jr, MD,† Michael J. Glantz, MD,† Kurt A. Jaeckle, MD,**
Haim Biran, MD,†† Martin Lesser, MD,‡‡ William A. Paulsen, MD,§§ Mary E. River, MD,¶¶
and Jerome B. Posner, MD*‡

Table 1: Clinical Characteristics of Anti-Ri-positive Patients

Patient	Age (yr)	Time From Neurological Diagnosis to Tumor Diagnosis (mo.)	Oculomotor Disorder	Ataxia		Other Symptoms and Signs	Tumor Diagnosis
				Appendicular	Truncal		
1	60	-2	Opsoclonus	+	+	Dizziness, nausea	Breast, 1986
2	70	+108	Nystagmus; abnormal pursuit	-	+	Nausea	Breast, 1978
3	47	+9	Opsoclonus	-	+ (severe)	Dizziness, nausea	Breast, Stage I, 1983
4	55	-2	None	+	+ (moderate)	Dysesthesias, proximal muscle weakness	Breast (Stage II-III), 1986
5	58	0.5	Opsoclonus rotatory nystagmus, 6th nerve palsies	+ (severe)	+ (severe)	Spastic quadriparesis; hyperreflexic, decreased hearing, right ear; swallowing difficulty	Axillary, 1988
6	73	No tumor	Opsoclonus?; nystagmus; ocular flutter	+ (moderate)	-	Dizziness, occasional diplopia, dysarthria, dementia, cerebral and cerebellar atrophy on MRI	None
7	62	+1	Opsoclonus	-	+	Dizziness, nausea	Fallopian tube, 1989
8	61	-5	Opsoclonus	+	+	Dizziness, blepharospasm	Breast, 1983

Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients

Setareh Shams'ili,¹ Joost Grefkens,¹ Bertie de Leeuw,¹ Martin van den Bent,¹ Herbert Hooijkaas,² Bronno van der Holt,³ Charles Vecht¹ and Peter Sillevius Smitt¹

Table 2 *Main clinical syndromes at presentation and high titre (≥ 400) paraneoplastic antineuronal autoantibodies detected over a 12-year period (1989–2001)*

Antibody	<i>n</i>	PCD (%)	PSN	PLE	PEM	POM	SPS
Anti-Hu	90	16 (18)	46	14	13	1	–
Anti-Yo	19	19 (100)	–	–	–	–	–
Anti-Tr	7	7 (100)	–	–	–	–	–
Anti-Ri	7	6 (86)	–	–	–	1	–
Anti-amphiphysin	7	–	4	1	1	–	1
Anti-CV2	5	–	3	1	1	–	–
Anti-mGluR1	2	2 (100)	–	–	–	–	–
Total	137	50 (37)	53	16	15	2	1

PSN = paraneoplastic sensory neuropathy; PLE = paraneoplastic limbic encephalitis; PEM = paraneoplastic encephalomyelitis; POM = paraneoplastic opsoclonus/myoclonus; SPS = stiff person syndrome.

Table 4 *Associated tumours in 50 PCD patients*

Antibody	<i>n</i>	Lung	Gynaecological	Breast	Hodgkin's	Other	No tumour
Anti-Yo	19	–	9	3	–	3	4
Anti-Hu	16	14	–	–	–	–	2
Anti-Tr	7	–	–	–	6	–	1
Anti-Ri	6	–	1	3	–	1	1
Anti-mGluR1	2	–	–	–	2	–	–
Total	50	14	10	6	8	4	8

Conclusion

- ❖ The present case further illustrates that recognition of PNS is important, since neurological symptoms almost invariably predate direct symptoms of the primary tumor, and **treatment at early stages** may provide better chance of good outcome.
- ❖ The presence of **anti-Ri antibody** typically identifies **women with opsoclonus/myoclonus and ataxia** who usually suffer from breast cancer.
- ❖ We have now illustrated the occurrence of **anti-Ri even in the absence of opsoclonus**, thus enlarging its clinical spectrum.
- ❖ In this way, our findings further reinforce the belief that **opsoclonus/myoclonus cannot be considered** syndromic of anti-Ri-antibody-associated paraneoplastic syndrome.

THANK YOU FOR YOUR ATTENTION

